Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire's Elaprase Follow-On's Future Uncertain After Trial Miss

Executive Summary

Specialty pharma says it will continue examining the full dataset for idursulfase formulation intended for pediatric Hunter syndrome patients with cognitive impairment.

You may also be interested in...



Deal Watch: Opportunity Knocks For Partnerships In Asia

ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.

Shire's Wellhoefer On Genetic Disease R&D And Expanding Access To Medicines

Scrip spoke with Shire's Head of Genetic Diseases, Medical Affairs, Hartmann Wellhoefer about upcoming milestones in the company's R&D pipeline and improving access to medicines for rare diseases after the Baxalta merger.

CinCor Plans Baxdrostat Phase III Despite Phase II Miss In Uncontrolled Hypertension

With subgroup analysis that it claims shows efficacy in non-Hispanics and success in a previous Phase II in treatment-resistant hypertension, CinCor plans to outline Phase III plans to FDA in early 2023.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC100087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel